 EXTON, Pa., May 18, 2021 GLOBE NEWSWIRE -- Idera Pharmaceuticals, Inc. Idera or the Company Nasdaq: IDRA today announced that it will not continue ILLUMINATE-301, the Companys trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival OS primary endpoint. The Company reported in March 2021 that the trial did not meet its primary endpoint of objective response rate ORR. Full results from the study will be presented in a future publication. 